Biotech Pharma Company Type/Product Area Amount Terms/Details (Month)
Company** (Symbol/Country)
(Country)
I. MODIFIED AGREEMENTS
Advanced Tissue Smith & Nephew Expansion of 4/96 $111M Companies signed binding letter
Sciences Inc. plc (U.K.) joint venture to com- (equity; of intent to expand joint venture;
mercialize Dermagraft % ND) Advanced Tissue gets $35M over
for treating diabetic next 12 months for additional
foot ulcers to include indications, including immediate
indications of venous $20M in equity purchase, $16M
and pressure ulcers as in milestones and 1-time payment
well as commercial- of $10M for demonstrating ability
ization of Dermagraft- of Dermagraft-TC for treating
TC for treating burns pressure sores (1/98)
Allelix Biophar- Eli Lilly Canada Expansion of 1989 ND Expansion will increase Lilly's
maceuticals Inc. Inc. (unit of Eli basic research collab- total investment in Allelix to
(Canada) Lilly and Co.; oration to apply new more than US$21M since partner-
NYSE:LLY) technologies to 2 drug ship began; collaboration already
discovery programs extended once in 1/95 (1/98)
(excitatory amino acid
receptors as targets for
drugs to treat central
nervous system dis-
orders; neuropeptide Y
receptor as target for
drugs to treat eating
disorders)
Alza Corp. Janssen Pharma- Expansion of agreement $21.5M Alza will make 1-time payment of
ceutica Inc. to develop an E-Trans $21.5M to Janssen and will share
(Belgium; unit of fentanyl product for operating profits from U.S. sales
Johnson & John- treating acute pain and get royalties on sales else-
son; NYSE:JNJ) (currently in Phase III where; Janssen has right to market
trials; uses electric cur- product and Alza has right to co-
rent to control drug promote in U.S. (1/98)
administration through
skin)
Aurora Eli Lilly and Co. Aurora provided ND Aurora and Lilly signed a collab-
Biosciences (NYSE:LLY) Lilly with a sublicense oration in 1/97 giving Lilly
Corp. and Sibia to Sibia's transcription- access to Aurora's technologies
Neurosciences based functional bio- for use in its internal drug discov-
Inc. assay for drug screening, ery program; Aurora and Sibia
to be used in conjunc- cross-licensed each other's drug
tion with Aurora's fluor- screening technologies in 1/97 and
escent assay technol- Aurora has now granted Lilly a
ogies and other drug sublicense; Sibia got up-front pay-
screening services ment, annual maintenance fees and
royalties (1/98)
Aurora Merck & Co. Inc. Aurora provided ND Aurora and Merck signed a collab-
Biosciences (NYSE:MRK) Merck with a sub- oration in 12/97 giving Merck
Corp. and Sibia license to Sibia's access to Aurora's technologies
Neurosciences patent on high-through- for use in its internal drug discov-
Inc. put drug screening, for ery program; Aurora and Sibia
use in conjunction cross-licensed each other's drug
with Aurora's fluor- screening technologies in 1/97 and
escent assay technol- Aurora now has granted Merck a
ogies and other drug sublicense; Sibia got up-front pay-
screening services ment (1/98)
Connetics Corp. Soltec Research Connetics exercised its ND Connetics gets exclusive rights to
Pty Ltd. option under 6/96 agree- develop and market product in
(Australia) ment to license clobeta- North America (1/98)
sol mousse for treating
severe dermatoses (high-
potency corticosteroid
formulated as quick-
break foam)
Corixa Corp. Pasteur Merieux Extension and expan- ND Relationship stems from prior
Connaught (unit sion of 3/97 collabora- option agreement for Pasteur Mer-
of Rhone-Poulenc tion on use of Corixa's ieux to license exclusive rights to
Group; France) protein adjuvant LeIF LeIF as adjuvant; now, Pasteur
(Leishmanial eukaryotic Merieux has received new option
initiation factor) in to commercialize LeIF in same
vaccines for infectious disease areas as previously; this
diseases; expanded to option expires 6/30/98 (1/98)
include comparisons of
LeIF to other adjuvants
SmithKline Extension of Smith- $2M As part of 3/97 cancer vaccine
Beecham Biologic- Kline's option under collaboration, Corixa granted
als SA (Belgium; 3/97 cancer vaccine SmithKline 2 options for licensing
unit of SmithKline agreement to license its programs for vaccine develop-
Beecham plc; early-stage antigen ment; SmithKline paid $2M to
NYSE:SBH; U.K.) discovery program for an extend the 1st option until 9/30/99
undisclosed cancer target (the 2nd option must be acted on
by 3Q:98) (2/98)
Cytel Corp. Nextran unit of Expansion and exten- ND New agreement allows for broader
Baxter Healthcare sion of 10/96 collab- application of Cytel's carbohy-
Corp. (NYSE:BAX) oration on Cytel's alpha drate products (made via sugar
galactose carbohydrate nucleotide cycling technology);
product for use in anti- Cytel has exclusive agreement to
transplant rejection supply products to Nextran; Cytel
device to include other gets milestones; Baxter invested
carbohydrate products $1M in Cytel's $8.4M private
for treating rejection placement (12/97); Cytel will
associated with xeno- develop and manufacture products
transplantation (2/98)
Emisphere Eli Lilly and Co. Expansion of 2/97 ND Lilly executed 2 license agree-
Technologies (NYSE:LLY) agreement to use ments and made 2 milestone pay-
Inc. Emisphere's technology ments to Emisphere (both are part
for oral delivery of of the terms of the original agree-
therapeutic proteins and ment) (3/98)
exercise of 2 options to
license technology for
2 specific Lilly proteins
(1 in osteoporosis; 1 in
endocrinology, including
growth disorders)
Epimmune Inc. G.D. Searle & Co. Definitive agreement $100M Letter of intent signed 9/97, at
(subsidiary of (wholly owned sub- to collaborate on cancer (13.4% which time Searle invested $5M
Cytel Inc.) sidiary of Monsanto vaccines developed via equity) in Cytel; in definitive agreement,
Co.; NYSE:MTC) Epimmune's library of Searle invested additional $3.9M
antigenic cancer epitopes in Cytel preferred stock and $6.1M
and immunostimulant in Epimmune preferred stock;
technology (PADRE) Cytel simultaneously invested
$3.9M in Epimmune preferred
stock; Searle now owns 13.4% of
Epimmune, while Cytel owns the
rest; preclinical and clinical mile-
stones could total $100M over
next 10-12 years; Searle gets world-
wide exclusive rights to Epimmune's
epitope and PADRE technologies
in cancer field (excluding rights
previously granted elsewhere);
Epimmune gets royalties (3/98)
Genome Schering-Plough Extension of 12/95 $7M Collaboration extended through
Therapeutics Corp. (NYSE:SGP) collaboration on anti- 3/31/00; guaranteed payments to
Corp. infective agents for drug- Genome Therapeutics raised from
resistant bacteria, includ- $13M to $20M (it can also get as
ing Staphylococcus much as $23.5M more in mile-
aureus, via Genome stones) (3/98)
Therapeutics' genomics-
based high-throughput
screening, target vali-
dation and assay
development
Human Genome Takeda Chemical Takeda exercised option ND Takeda exercised its option to
Sciences Inc. Industries Ltd. under 6/95 agreement develop and commercialize pro-
(Japan) to license Human Ge- duct in Japan; Human Genome
nome's genomics-derived got option fee for these rights and
product candidate mye- will get milestones and royalties;
loid progenitor inhibitory further details ND (2/98)
factor-1 (currently in U.S.
Phase I trials for protecting
hematopoietic progenitor
cells from effects of
chemotherapy)
Incyte Novartis AG Expansion of 6/97 ND Novartis gets nonexclusive access
Pharmaceuticals (Switzerland) database partnership to LifeSeq database in exchange
Inc. to include Incyte's for annual access fees; further
LifeSeq gene sequence details ND (1/98)
and expression database
Pfizer Inc. Extension and expan- ND Pfizer will continue to have access
(NYSE:PFE) sion of 6/94 genomic to Incyte's databases, including
database partnership to its LifeSeq gene sequence and
include LifeSeq FL data- expression database as well as
base of full-length genes others; collaboration extended for
and LifeSeq GeneAlbum 3 years (intent announced 12/97);
DNA clone set financial details ND (2/98)
LeukoSite Inc. Warner-Lambert Extension of 11/96 ND Two-year extension of collabora-
Co. (NYSE:WLA) collaboration on small tion (already expanded once in
molecule antagonists to 11/97) (1/98)
the CCR5 and CXCR4
receptors (chemokine
coreceptors used by
HIV to enter T cells)
Ligand Eli Lilly and Co. Extension of Ligand's $20M Lilly extended Ligand's option so
Pharmaceuticals (NYSE:LLY) option (under 11/97 that Ligand has additional time to
Inc. alliance on meta- complete its evaluation and asses-
bolic diseases) to ment of product; if Ligand exer-
acquire selected rights cises option, Lilly gets milestones
to 1 of Lilly's specialty of $20M in Ligand stock; if Ligand
drugs in certain mar- does not exercise option, it can
kets of interest to elect to sell $20M in equity to
Ligand Lilly at 20% premium to market
(3/98)
SmithKline Expansion of 2/95 ND The collaboration was expanded
Beecham plc collaboration on small twice; in 2/97, SmithKline exer-
(NYSE:SBH; U.K.) molecule, orally available cised its option to include a 3rd
drugs to control hemato- drug discovery target and bought
poiesis; use of Ligand's $2.5M in Ligand stock; in 8/97,
STAT technology (signal SmithKline extended the term of
transducers and activators the collaboration and bought a
of transcription) to target $2.5M convertible note (although
hematopoietic growth both these events occurred in 1997,
factors Ligand announced them in 1998)
(3/98)
MedImmune Inc. SmithKline Finalized agreement $85M Agreement, proposed 12/97, was
Beecham plc (from 12/97) to develop subject to clearance under anti-
(NYSE:SBH; U.K.) human papillomavirus trust laws, which occurred (1/98)
(HPV) vaccines for pre-
venting cervical cancer
and genital warts
Onyx Parke-Davis Extension of 5/95 $25M Collaboration extended for 3 years;
Pharmaceuticals (division of collaboration on drugs Onyx gets $25M in committed
Inc. Warner-Lambert Co.; that affect cell-cycle funding plus milestones; Warner-
NYSE:WLA) regulation; for treat- Lambert also gets marketing rights
ing cancer and hyper- in Japan (as well as rest of world);
proliferative diseases Onyx gets milestones tied specifi-
cally to development efforts in
Japan (1/98)
OSI Pharma- Wyeth-Ayerst Exercise of option to ND Wyeth-Ayerst gets exclusive
ceuticals Inc. Laboratories license series of small worldwide license to compounds;
(division of Ameri- molecule, gene-transcrip- further details ND (1/98)
can Home Products tion-based compounds
Corp.; NYSE:AHP) that modulate expression
of phosphoenol pyruvate
carboxykinase (PEPCK) for
treating Type II diabetes
Repligen Corp. Glaxo Wellcome Extension of 11/94 ND One-year extension; Glaxo will use
plc (NYSE:GLX; U.K.) collaboration on chemo- assay to screen its internal com-
kine inhibitors; com- pound library; Repligen will
panies have jointly supply Glaxo with 1 of its carbo-
developed high-through- hydrate analogue combinatorial
put screening assay to libraries for screening, too; Glaxo
identify small molecules gets worldwide rights to any prod-
that block interaction of ucts; Repligen gets research sup-
pro-inflammatory chemo- port and royalties; Glaxo has
kine with its receptor option to acquire rights to active
compounds from Repligen's
library (1/98)
Ribozyme Parke-Davis Definitive agreement ND Letter of intent signed 12/97;
Pharmaceuticals (division of on collaboration to Ribozyme Pharmaceuticals will
Inc. Warner-Lambert Co.; evaluate specific disease- design and synthesize ribozymes
NYSE:WLA) related genes for drug against target genes designated by
intervention using Parke-Davis; financial terms ND
Ribozyme's target val- (3/98)
idation technology
(involves use of ribo-
zymes to discover gene
function and validate
gene targets)
Trega Ono Pharmaceutical Letter of intent to ND Ono will fund additional research
Biosciences Inc. Co. Ltd. (Japan) expand 6/97 collabor- and pay milestones and royalties;
ation on orally active Trega will optimize and screen
small molecules for lead compounds discovered by
treating diseases medi- Ono in new area of interest; other
ated by melanocortin details ND (2/98)
receptor (i.e., inflam-
matory diseases) to
include a new target of
interest to Ono
Vimrx Baxter Healthcare Official naming of new $130M Companies signed letter of intent
Pharmaceuticals Corp. (subsidiary of cell therapy company (equity; to form the new company (which
Inc. Baxter International Nexell Therapeutics % ND) is 80% owned by Vimrx and 20%
Inc.; NYSE:BAX) Inc. (formed in 1997 owned by Baxter) in 6/97; the
to develop cell therapies definitive agreement was signed in
for cancer and other 10/97 and Vimrx shareholders
diseases by combining approved the deal in 12/97; Baxter
Baxter's ex vivo cellular and Vimrx together contributed
selection and storage $40M to fund Nexell; Baxter is
business with Vimrx's responsible for manufacturing,
access to gene therapy sales, marketing and distribution
and genomics technology) of products; Nexell will focus on
R&D, partnerships and marketing
development (2/98)
II. TERMINATED AGREEMENTS
Amylin Johnson & Johnson Termination of 6/95 — Johnson & Johnson provided 6
Pharmaceuticals (NYSE:JNJ) collaboration on Pram- months' notice of its intent to
Inc. lintide (synthetic ana- terminate the collaboration, saying
logue of human hormone it was no longer in its best inter-
amylin) for treating ests; all product rights return to
Types I and II diabetes Amylin, which will restructure its
(currently in Phase III operations and reduce workforce
trials) by 25% so it can continue product
development (3/98)
Anergen Inc. Novo Nordisk A/S Termination of 8/93 — This collaboration was extended
(NYSE:NVO; collaboration on use of for 2 years in 4/96, but Novo has
Denmark) AnergiX technology now terminated it, as part of its
(inactivates disease- change in strategic direction; all
related T cells) for product rights return to Anergen;
various diseases, includ- Novo will reimburse Anergen for
ing multiple sclerosis cost of ongoing clinical trial; Aner-
(Phase I trial ongoing) gen has no future obligations to
Novo; Anergen will restructure its
operations and reduce workforce
(2/98)
Immusol Inc.* Pfizer Inc. Conclusion of 3/95 — Partnership will not be renewed;
(NYSE:PFE) collaboration to Pfizer will fund program through
develop ribozyme gene 5/98, after which Immusol will
therapy for treating continue product development
HIV infection (program (HIV gene therapy currently in
was part of Pfizer's Phase I trials) (3/98)
R&D initiative
Pfizergen)
NaPro Baker Norton Termination of 1993 $14.5M Partners terminated their agree-
BioTherapeutics Pharmaceuticals development and ment after the FDA ruled in 12/97
Inc. Inc. (wholly owned marketing agreement that Ivax's paclitaxel-based drug
subsidiary of Ivax on paclitaxel (compound Paxene for treating AIDS-related
Corp.; AMEX:IVX) extracted from needles Kaposi's sarcoma might not get
and limb stock of marketing approval until 8/04;
ornamental yew trees) Ivax gets royalty-free, nonexclu-
sive license to NaPro's pending
patents on stable formulation of
paclitaxel in U.S., Europe and cer-
tain other markets; NaPro gets
$6M cash, $6.4M on issuance of
patents and the return of 1.1M
shares of its stock ($2.1M) held by
Ivax; NaPro will supply a certain
amount of paclitaxel to Ivax (3/98)
NOTES:
# This chart contains information on modified and terminated agreements only, covering the time period between 1/1/98 and 3/24/98. It does not include arrangements that are classed strictly as production, marketing and/or distribution agreements, nor does it include any collaborations that involve agricultural product development.
For a chart listing new collaborations between big pharma and biotech companies for the same time period (1/1/98 - 3/24/98), see the 3/30/98 issue of BioWorld Financial Watch.
ND = Not disclosed, reported and/or available
* Private companies are indicated with an asterisk.
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 13-14.